Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (referred to as Chemomab Therapeutics Ltd. in metadata) covers the month of March 2019. The filing serves to announce the company's fourth quarter and full year 2018 financial results, which were released via a press release on March 12, 2019.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1) and are not explicitly stated in the body of this Form 6-K.
Material Changes
The filing does not disclose specific material changes versus prior periods. It only references the announcement of the Q4 and full-year 2018 results without detailing the comparative performance in the text provided.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, specific risk factors, contingencies, or unusual items. The document functions solely as a notice of the press release attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 12, 2019) for actual financial figures.
- Verify the specific revenue and net loss figures for Q4 and full-year 2018.
- Check the cash balance and burn rate disclosed in the press release.
- Confirm any updates on clinical trial progress or regulatory milestones mentioned in the full press release.